EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy

Jie Shi, Zijian Zhang, Hsin-Yi Chen, Yingmeng Yao, Shanwen Ke, Kechun Yu, Jiangzhou Shi, Xiangling Xiao, Chuan He, Bolin Xiang, Yishuang Sun, Minling Gao und 10 weitere

Molecular Therapy · 2025-03 · 33 (3) · 1073-1090

DOI: 10.1016/j.ymthe.2025.01.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-03. Verfasst von Jie Shi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Hubei Key Laboratory…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Immunotherapy, Adoptive, Immune Checkpoint Inhibitors, Ribonucleoproteins. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, Natural Science Foundation of Sichuan Province, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of T cells is a major limitation for the clinical success of T cell-based cancer immunotherapies , such as immune checkpoint blockade and chimeric antigen receptor (CAR)-T cell therapy. Understanding the underlying mechanisms for regulating T cell functions can facilitate designing therapeutic strategies to improve immunotherapies . Here, we report that TRIM21 impairs CD8 + T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzes the K63-linked ubiquitination on programmed cell death-1 (PD-1) at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation. Thus, Trim21 knockout (KO) significantly decreases PD-1 expression and enhances the activation of cytotoxic CD8 + T cells, which sensitizes tumors to anti-CTLA-4 immunotherapy. Notably, Trim21 KO anti-CD19 CAR-T cells exhibit improved anti-tumor efficacy. These results reveal the molecular mechanism by which TRIM21-mediated K63-linked ubiquitination on PD-1 restrains the activation of CD8 + T cells, highlighting that targeting the TRIM21-PD-1 axis as a potential therapeutic strategy to potentiate cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorImmunotherapy, AdoptiveImmune Checkpoint InhibitorsRibonucleoproteinsReceptors, Chimeric AntigenHumansAnimalsCD8-Positive T-LymphocytesMiceUbiquitinationCell Line, TumorLymphocyte ActivationNeoplasmsSS-A Antigen

Stichwörter der Autor:innen

CAR-T therapyK63-linked ubiquitinationPD-1TRIM21cancer immunotherapy

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsRibonucleoproteinsReceptors, Chimeric AntigenSS-A AntigenPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Cent…
  • Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan 430065, China; Key Laboratory of Tropical Biological Resources of Ministry of Education, School o…
  • Institute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan.
  • Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan 430065, China.
  • Department of Life Sciences and Institute of Genome Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan; Cancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 1123…
  • Institute of Biomedical Sciences, Academia Sinica, Taipei 115201, Taiwan; Taiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 112304, Taiwan.

Förderung

  • National Science and Technology Council
  • Natural Science Foundation of Sichuan Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Hubei Province

Zitieren

APA

Shi, J., Zhang, Z., Chen, H. Y., Yao, Y., Ke, S., Yu, K., Shi, J., Xiao, X., He, C., Xiang, B., Sun, Y., Gao, M., Xing, X., Yu, H., Wang, X., Yuan, W. C., Budiarto, B. R., Chen, S. Y., Zhang, T., …, & Zhang, J. (2025). Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Molecular Therapy, 33(3), 1073-1090. https://doi.org/10.1016/j.ymthe.2025.01.047

Vancouver

Shi J, Zhang Z, Chen HY, Yao Y, Ke S, Yu K, et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Molecular Therapy. 2025;33(3):1073-1090. doi:10.1016/j.ymthe.2025.01.047

BibTeX
@article{Shi2025,
  author = {Shi, Jie and Zhang, Zijian and Chen, Hsin-Yi and Yao, Yingmeng and Ke, Shanwen and Yu, Kechun and Shi, Jiangzhou and Xiao, Xiangling and He, Chuan and Xiang, Bolin and Sun, Yishuang and Gao, Minling and Xing, Xixin and Yu, Haisheng and Wang, Xiyong and Yuan, Wei-Chien and Budiarto, Bugi Ratno and Chen, Shih-Yu and Zhang, Tongcun and Lee, Yu-Ru and Zhu, Haichuan and Zhang, Jinfang},
  title = {Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {3},
  pages = {1073--1090},
  doi = {10.1016/j.ymthe.2025.01.047}
}
Kostenlos starten →